To facilitate translation of 18 F-FACE into the clinic and in preparation to a phase I clinical study, we have conducted studies aimed at assessing the pharmacokinetics, biodistribution, metabolism, radiation dosimetry, and acute toxicity of diagnostic dosages of 18 F-FACE in rhesus macaques.

Mar 25, 2011 · To facilitate the clinical translation of 18F-fluoroacetate (18F-FACE), the pharmacokinetics, biodistribution, radiolabeled metabolites, radiation dosimetry, and pharmacological safety of diagnostic doses of 18F-FACE were determined in non-human primates. 18F-FACE was synthesized using a custom-built automated synthesis module.

Fluorine-18 (18 F, also called radiofluorine) is a fluorine radioisotope which is an important source of positrons. It has a mass of 18.0009380 (6) u and its half-life is 109.771 (20) minutes. It decays by positron emission 96.7% of the time and electron capture 3.3% of the time. Both modes of decay yield stable oxygen-18.

To assess the clinical impact of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET-CT) compared with contrast-enhanced computed tomography (CECT) in patients referred via the Specialist Skin Cancer Multidisciplinary ...

Positron emission tomography (PET) is an attractive technique to gain a non-invasive assessment of tumor hypoxia within the whole tumor, with 18F-fluoromisonidazole (18F-FMISO) and 18F-flouroazomycin arabinoside (18F-FAZA) being the most promising radiotracers.

However, the short half-life (20.4 min) of 11C limits the general availability of 11C-ACE. 18F-Fluoroacetate (18F-FAC) is an analog of acetate with a longer radioactive half-life (18F = 110 min). This study was undertaken to assess the potential usefulness of 18F-FAC as a prostate tumor imaging agent.

Mar 6, 2014 · [18F]-fluoroacetate (18F-FACE) is an [18F] fluorinated acetate, which is known to be converted into fatty acids, incorporated in membrane and is expected to be a promising oncologic PET tracer. The aim of this study was to evaluate the usefulness of 18F-FACE as an oncologic PET tracer in preclinical study in healthy volunteers and in patients ...

Introduction To facilitate the clinical translation of 18F-fluoroacetate (18F-FACE), the pharmacokinetics, biodistribution, radiolabeled metabolites, radiation dosimetry, and pharmacological safety of diagnostic doses of 18F-FACE were determined in

Mar 1, 2011 · A rapid accumulation of (18)F-FACE-derived radioactivity was observed in the liver and kidneys, followed by clearance of the radioactivity into the intestine and the urinary bladder.

We here examined changes in brain uptake of [18F]FACE by PET during cerebral ischemia, in combination with immunohistochemistry study for confirming glial cell activation associated with neuroinflammation.